Drug

Cp-547632 clinical trials

Also written CP-547,632.

studies test it: 7
open now: 1
in phase 3: 0
first study started: 2002

How each study uses cp-547632 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the cp-547632 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: Not in FDA's approval records
European Union: Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

PAN-90806 Eye Drops: 3
PAN-90806 Ophthalmic Solution: 3

Development codes

CP-547,632: 3

Studies by the year they started

7 studies that test it; most in 2002 (1)

Studies that test cp-547632, by start year
Year	Studies
2002	1
2003	1
2004	1
2014	1
2015	1
2018	1
2026	1

By phase

A phase 1/2 study counts in both.

Phase 1: 5
Phase 2: 4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Macular Degeneration: 3
Diabetic Retinopathy: 1
Fallopian Tube Neoplasms: 1
Lung Neoplasms: 1
Ovarian Neoplasms: 1

Who runs them

Industry 6 · Other 1

PanOptica, Inc. (3) · Pfizer (2) · Jonsson Comprehensive Cancer Center (1) · Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. (1)

Related medicines

As reviewed, each with the page that says it.

One of Protein Kinase Inhibitors source
One of Tyrosine kinase inhibitors (TKIs) source

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test cp-547632.

Dec 2026Evaluation of PAN-90806 Eye Drops in Healthy SubjectsPhase 1 · Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

Studies

Open first, then newest update. How each study uses cp-547632 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 7

Codes

What other systems call cp-547632 · ClinicalTrials.gg INT004599

UNII (FDA) W1B375O5M2CP-547632Confirmed FDA, Wikidata
Wikidata Q27076896cp-547632Confirmed FDA, Wikidata
NCI Thesaurus C93263CP-547632One source FDA
DrugBank DB12962One source Wikidata

System	Code	Name there	Checked by
UNII (FDA)	W1B375O5M2	CP-547632	Confirmed FDA, Wikidata
Wikidata	Q27076896	cp-547632	Confirmed FDA, Wikidata
NCI Thesaurus	C93263	CP-547632	One source FDA
DrugBank	DB12962	—	One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.